CD4+ T effector memory cell dysfunction is associated with the accumulation of granulocytic myeloid-derived suppressor cells in glioblastoma patients

Neuro-Oncology

Volumn 18, Issue 6, 2016, Pages 807-818

  Dubinski, Daniel ^a,c   Wölfer, Johannes ^b   Hasselblatt, Martin ^b   Schneider Hohendorf, Tilman ^b   Bogdahn, Ulrich ^a   Stummer, Walter ^b   Wiendl, Heinz ^b   Grauer, Oliver M ^b  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

glioblastoma; myeloid derived suppressor cell; PD 1; PD L1; T effector memory cell

Indexed keywords

ARGINASE 1; CD14 ANTIGEN; CD15 ANTIGEN; CD16 ANTIGEN; GAMMA INTERFERON; HLA DR ANTIGEN; INTERLEUKIN 4 RECEPTOR ALPHA; PROGRAMMED DEATH 1 LIGAND 1; PROGRAMMED DEATH 1 RECEPTOR; REACTIVE OXYGEN METABOLITE; STEROID;

ADULT; AGED; ARTICLE; BIOACCUMULATION; BRAIN SURGERY; CD4+ T EFFECTOR MEMORY CELL; COCULTURE; CONTROLLED STUDY; CYTOKINE RELEASE; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; GLIOBLASTOMA; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; NEUTROPHILIC MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PROTEIN EXPRESSION; T LYMPHOCYTE; UPREGULATION; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CYTOLOGY; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE; MYELOID-DERIVED SUPPRESSOR CELL; PATHOLOGY; PHYSIOLOGY; PROCEDURES;

CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COCULTURE TECHNIQUES; FLOW CYTOMETRY; GLIOBLASTOMA; HUMANS; IMMUNOLOGIC MEMORY; LYMPHOCYTE ACTIVATION; MONOCYTES; MYELOID CELLS; MYELOID-DERIVED SUPPRESSOR CELLS;

EID: 84975134210     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nov280     Document Type: Article

References (32)

1. Nagaraj S, Gabrilovich DI. Myeloid-derived suppressor cells in human cancer. Cancer J. 2010;16(4):348-353.
2. Condamine T, Gabrilovich DI. Molecular mechanisms regulating myeloid-derived suppressor cell differentiation and function. Trends Immunol. 2011;32(1):19-25.
3. Rodrigues JC, Gonzalez GC, Zhang L, et al. Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol. 2010;12(4):351-365.
4. Solito S, Marigo I, Pinton L, Damuzzo V, Mandruzzato S, Bronte V. Myeloid-derived suppressor cell heterogeneity in human cancers. Ann N Y Acad Sci. 2014;1319:47-65.
5. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009;9(3): 162-174.
6. Peranzoni E, Zilio S, Marigo I, et al. Myeloid-derived suppressor cell heterogeneity and subset definition. Curr Opin Immunol. 2010; 22(2):238-244.
7. Raychaudhuri B, Rayman P, Ireland J, et al. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol. 2011;13(6): 591-599.
8. Sippel TR, White J, Nag K, et al. Neutrophil degranulation and immunosuppression in patients with GBM: restoration of cellular immune function by targeting arginase I. Clin Cancer Res. 2011; 17(22):6992-7002.
9. Felsberg J, Rapp M, Loeser S, et al. Prognostic significance of molecular markers and extent of resection in primary glioblastoma patients. Clin Cancer Res. 2009;15(21):6683-6693.
10. Schroeteler J, Reeker R, Suero Molina E, et al. Glioma tissue obtained by modern ultrasonic aspiration with a simple sterile suction trap for primary cell culture and pathological evaluation. Eur Surg Res. 2014;53(1-4):37-42.
11. Grauer OM, Nierkens S, Bennink E, et al. CD4+FoxP3+ regulatory T-cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo. Int J Cancer. 2007;121(1):95-105.
12. Jacobs JF, Idema AJ, Bol KF, et al. Regulatory T-cells and the PD-L1/PD-1 pathway mediate immune suppression in malignant human brain tumors. Neuro Oncol. 2009;11(4):394-402.
13. Gielen PR, Schulte BM, Kers-Rebel ED, et al. Increase in both CD14-positive and CD15-positive myeloid-derived suppressor cell subpopulations in the blood of patients with glioma but predominance of CD15-positive myeloid-derived suppressor cells in glioma tissue. J Neuropathol Exp Neurol. 2015;74(5):390-400.
14. Raychaudhuri B, Rayman P, Huang P, et al. Myeloid derived suppressor cell infiltration of murine and human gliomas is associated with reduction of tumor infiltrating lymphocytes. J Neurooncol. 2015;122(2):293-301.
15. Umemura N, Saio M, Suwa T, et al. Tumor-infiltrating myeloidderived suppressor cells are pleiotropic-inflamed monocytes/ macrophages that bear M1-and M2-type characteristics. J Leukoc Biol. 2008;83(5):1136-1144.
16. Kohanbash G, McKaveney K, Sakaki M, et al. GM-CSF promotes the immunosuppressive activity of glioma-infiltrating myeloid cells through interleukin-4 receptor-alpha. Cancer Res. 2013;73(21): 6413-6423.
17. Gros A, Turcotte S, Wunderlich JR, Ahmadzadeh M, Dudley ME, Rosenberg SA. Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma. Clin Cancer Res. 2012;18(19):5212-5223.
18. Haverkamp JM, Crist SA, Elzey BD, Cimen C, Ratliff TL. In vivo suppressive function of myeloid-derived suppressor cells is limited to the inflammatory site. Eur J Immunol. 2011;41(3): 749-759.
19. Beckhove P, Feuerer M, Dolenc M, et al. Specifically activated memory T-cell subsets from cancer patients recognize and reject xenotransplanted autologous tumors. J Clin Invest. 2004; 114(1):67-76.
20. Attig S, Hennenlotter J, Pawelec G, et al. Simultaneous infiltration of polyfunctional effector and suppressor T-cells into renal cell carcinomas. Cancer Res. 2009;69(21):8412-8419.
21. Wherry EJ. T-cell exhaustion. Nat Immunol. 2011;12(6):492-499.
22. Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T-cells is associated with T-cell exhaustion and disease progression. Nature. 2006;443(7109):350-354.
23. Lang KS, Recher M, Navarini AA, et al. Inverse correlation between IL-7 receptor expression and CD8 T-cell exhaustion during persistent antigen stimulation. Eur J Immunol. 2005;35(3): 738-745.
24. Thompson RH, Dong H, Lohse CM, et al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin Cancer Res. 2007;13(6):1757-1761.
25. Ahmadzadeh M, Johnson LA, Heemskerk B, et al. Tumor antigen-specific CD8 T-cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114(8): 1537-1544.
26. Wintterle S, Schreiner B, Mitsdoerffer M, et al. Expression of the B7-related molecule B7-H1 by glioma cells: a potential mechanism of immune paralysis. Cancer Res. 2003;63(21):7462-7467.
27. Bloch O, Crane CA, Kaur R, Safaee M, Rutkowski MJ, Parsa AT. Gliomas promote immunosuppression through induction of B7-H1 expression in tumor-associated macrophages. Clin Cancer Res. 2013;19(12):3165-3175.
28. NomanMZ, Desantis G, Janji B, et al. PD-L1 is a novel direct target of HIF-1alpha, and its blockade under hypoxia enhanced MDSCmediated T-cell activation. J Exp Med. 2014;211(5):781-790.
29. Nagaraj S, Nelson A, Youn JI, Cheng P, Quiceno D, Gabrilovich DI. Antigen-specific CD4(+) T-cells regulate function of myeloidderived suppressor cells in cancer via retrograde MHC class II signaling. Cancer Res. 2012;72(4):928-938.
30. Schuster J, Lai RK, Recht LD, et al. A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study. Neuro Oncol. 2015;17(6):854-861.
31. Lei GS, Zhang C, Lee CH. Myeloid-derived suppressor cells impair alveolar macrophages through PD-1 receptor ligation during Pneumocystis pneumonia. Infect Immun. 2015;83(2): 572-582.
32. Hoepner S, Loh JM, Riccadonna C, et al. Synergy between CD8 T-cells and Th1 or Th2 polarised CD4 T-cells for adoptive immunotherapy of brain tumours. PLoS One. 2013;8(5): e63933.